Differential Regulation of Cathepsin S and Cathepsin L in Interferon γ–treated Macrophages by Beers, Courtney et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/01/169/11 $8.00
Volume 197, Number 2, January 20, 2003 169–179
http://www.jem.org/cgi/doi/10.1084/jem.20020978
 
169
 
Differential Regulation of Cathepsin S and Cathepsin L in 
Interferon 
 
 
 
–treated Macrophages
 
Courtney Beers,
 
1 
 
Karen Honey,
 
1, 2 
 
Susan Fink,
 
3 
 
Katherine Forbush,
 
1, 2
 
and Alexander Rudensky
 
1, 2
 
1
 
Department of Immunology, 
 
2
 
Howard Hughes Medical Institute, and 
 
3
 
School of Medicine, University of 
Washington, Seattle, WA 98195
 
Abstract
 
Cathepsin S (catS) and cathepsin L (catL) mediate late stages of invariant chain (Ii) degradation
in discrete antigen-presenting cell types. Macrophages (M
 
 
 
s) are unique in that they express
both proteases and here we sought to determine the relative contribution of each enzyme. We
observe that catL plays no significant role in Ii cleavage in interferon (IFN)-
 
 
 
–stimulated M
 
 
 
s.
In addition, our studies show that the level of catL activity is significantly decreased in M
 
 
 
s
cultured in the presence of IFN-
 
  
 
whereas catS activity increases. The decrease in catL activity
upon cytokine treatment occurs despite the persistence of high levels of mature catL protein,
suggesting that a specific inhibitor of the enzyme is up-regulated in IFN-
 
 
 
–stimulated perito-
neal M
 
 
 
s. Similar inhibition of activity is observed in dendritic cells engineered to overexpress
catL. Such enzymatic inhibition in M
 
 
 
s exhibits only partial dependence upon Ii and there-
fore, other mechanisms of catL inhibition are regulated by IFN-
 
 
 
. Thus, during a T helper cell
type 1 immune response catL inhibition in M
 
 
 
s results in preferential usage of catS, such that
major histocompatibility complex class II presentation by all bone marrow–derived antigen-
presenting cell is regulated by catS.
Key words: cathepsin • macrophage • Ii processing • IFN-
 
  
 
• p41
 
Introduction
 
MHC class II molecules expressed on the surface of APCs
present proteolytic fragments of self- and foreign protein an-
 
tigens to CD4
 
  
 
T cells (1). MHC class II molecules assemble
in the endoplasmic reticulum with the help of the chaper-
 
one molecule invariant chain (Ii),
 
*
 
 a type II glycoprotein
that promotes the proper folding and assembly of the MHC
 
class II 
 
 
 
/
 
  
 
heterodimer (2, 3). The Ii cytoplasmic tail con-
tains a sequence targeting this complex to the lysosomal/en-
dosomal pathway (4, 5) where it is exposed to the activity of
proteases including cathepsins, which mediate cleavage of Ii
in a step-wise manner, leaving only the class II–associated Ii
peptide associated with the MHC class II peptide binding
groove (6–8). Before MHC class II trafficking to the cell
surface, the MHC-like molecule HLA-DM (H-2M in
mice) mediates removal of class II–associated Ii peptide in
exchange for the diverse array of self- and nonself-peptides
generated in the endosomes and lysosomes (9, 10).
The cathepsins are a large family of aspartyl (D and E)
and cysteinal (B, S, and L) endosomal proteinases. Recent
studies have indicated that cathepsin S (catS) and cathepsin
L (catL) are differentially expressed in APCs and are the
only identified enzymes from this family of proteinases to
play a key role in regulating MHC class II presentation
(11–14). CatS is expressed in B cells and dendritic cells
(DCs) and catL activity is observed in cortical thymic epi-
thelial cells whereas in macrophages (M
 
 
 
s) both catL and
catS activity can be detected (11–14). In B cells and DCs
catS mediates the late stages of Ii degradation, specifically
cleavage of the p22 and p12 Ii fragments and therefore reg-
ulates presentation of exogenous peptides in the context of
MHC class II (12–14). CatL-deficient mice, however, ex-
hibit a profound defect in CD4
 
  
 
T cell selection as a result
of the role played by catL in cleavage of these Ii fragments
and in generation of the MHC class II bound peptides in
cortical thymic epithelial cells (11, 15).
The observation that M
 
 
 
s express both of the cysteinal
proteinases that mediate the late stages of Ii degradation has
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lead several groups to investigate the relative contribution
of each enzyme to regulation of MHC class II presentation
by these cells. One previous study reported that in alveolar
and peritoneal M
 
 
 
s (pM
 
 
 
s) lacking both catS and catL,
degradation of Ii occurs as a result of activity of additional
cysteine proteinases, potentially cathepsin F (catF; reference
16). However, we have previously observed a role for catS
in regulating MHC II presentation of some exogenous an-
tigens by M
 
 
 
s (13). Thus, we sought to further investigate
the roles of catS and catL in regulating MHC class II pre-
sentation by M
 
 
 
s and determine the extent to which the
functions of these two enzymes overlap. We demonstrate
that catS mediates degradation of the p12 fragment of Ii in
IFN-
 
 
 
–stimulated pM
 
 
 
s whereas catL plays no significant
role in this process. In addition, we show this is a result of
down-regulation of intracellular catL activity and increased
catS activity in pM
 
 
 
s after stimulation with this cytokine.
This decrease in catL activity correlates with a decrease in
mRNA levels, although IFN-
 
 
 
–treated pM
 
 
 
s maintain
high levels of mature catL protein. We also found catL ac-
tivity secreted upon IFN-
 
  
 
treatment of pM
 
 
 
, which cor-
relates with a small increase in the amount of secreted ma-
ture catL protein. However, as the total amount of secreted
catL protein (pro-form plus mature form) and the amount
of intracellular mature catL protein is not altered upon
IFN-
 
  
 
treatment of pM
 
 
 
s, we believe secretion of catL
does not account for the down-modulation of catL activity.
These data suggest that a specific inhibitor of catL activity is
up-regulated upon IFN-
 
  
 
stimulation of pM
 
 
 
s. Further-
more, we also report complete inhibition of catL activity
when catL protein is overexpressed in DCs, suggesting that
bone marrow–derived APCs i.e., DCs and M
 
 
 
s, may ex-
press a catL-specific inhibitor. We found no significant evi-
dence to suggest the p41 isoform of Ii effects such inhibi-
tion of catL activity in pM
 
 
 
s. These results lead us to
hypothesize that during a Th1 type immune response, catS
activity in pM
 
 
 
s is critical for Ii degradation and hence
MHC class II antigen presentation.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6) mice were purchased from Charles
River Laboratories and maintained under specific pathogen-free
conditions at the University of Washington. CatS
 
 
 
/
 
 
 
, catL
 
 
 
/
 
 
 
,
catS
 
 
 
/
 
  
 
  
 
catL
 
 
 
/
 
 
 
, and Ii
 
 
 
/
 
  
 
animals were bred and maintained
under these same conditions. CD11c-catL mice were generated us-
ing the CD11c-E
 
 
 
d 
 
construct (provided by K. Karjalainen, The
Basel Institute for Immunology, Basel, Switzerland; reference 17).
E
 
 
 
d 
 
was removed and catL cDNA was inserted into the construct
by blunt end ligation using BamH1. CatL was flanked on either
side by rabbit 
 
  
 
globin gene fragments and provides the transgene
with an intron and a polyadenylation signal. To generate CD11c-
catL transgenic (tg) mice, purified DNA was injected into BDF1 
 
 
 
B6 fertilized embryos. Offspring were backcrossed with catS
 
 
 
/
 
  
 
B6
mice. CD4
 
  
 
T cell development occurred normally in the CD11c-
catL tg mice and their CD4/CD8 T cell ratio was comparable to
that observed in non-tg littermate control animals. All animals
were used at 2–8-mo of age. All procedures and care of the animals
were in accordance with University of Washington guidelines.
 
Antibodies.
 
The polyclonal rabbit antisera to mouse catL
(provided by A. Erickson, University of North Carolina, Chapel
Hill, NC) and the monoclonal antibodies M5/114 (anti-I-A
 
b, d, q
 
and anti-E
 
d, k
 
) and IN-1 (anti-Ii) have been described previously
(18–20). Streptavidin horseradish peroxidase was purchased from
Vector Laboratories.
 
M
 
  
 
Isolation.
 
To elicit pM
 
 
 
s, mice were injected intraperito-
neally with 1 ml 4% thioglycollate (Becton Dickinson) and peri-
toneal exudate cells were collected 4–5 d later. M
 
 
 
s were cul-
tured in Hydron-treated (Hydro Med Sciences) plates with
RPMI-S (RPMI 1640 containing 100 u penicillin-streptomycin,
2 mM 
 
l
 
-Glutamine [Invitrogen Corporation], and 10% FBS
[GIBCO BRL]). Bone marrow–derived M
 
 
 
s (BMM
 
 
 
s) were
generated by culturing bone marrow cells on bacterial plastic
plates in RPMI-S with 10
 
6 
 
units/ml M-CSF (21). Mouse alveolar
M
 
 
 
s were harvested from lavage fluids as previously described
(22). In brief, mouse lung was washed repeatedly with 1 ml of 6
mM EDTA PBS. M
 
 
 
s were pelleted and cultured in RPMI-S.
For cytokine treatment, M
 
  
 
populations were cultured for 48 h
in the presence or absence of 0.3 ng/ml recombinant mouse IFN-
 
 
 
(R&D Systems) or 200 U/ml recombinant mouse IL-4 (23).
 
DC Isolation.
 
Spleens were enriched for DCs as previously
described (14, 24). In brief, mice were injected subcutaneously
with 5 
 
  
 
10
 
6 
 
Flt3 ligand secreting B16 melanoma cells (provided
by G. Dranoff, Dana-Farber Cancer Institute, Boston, MA) and
spleens were harvested after the tumors reached 2 cm in diameter.
Splenocytes were incubated with magnetic CD11c microbeads
(Miltenyi Biotec), positively selected on an AutoMACS, and the
purity of the positive fraction was assessed by flow cytometric
analysis. All positive fractions were 
 
 
 
96% CD11c
 
hi
 
.
 
Cysteine Protease Active Site Labeling.
 
10
 
6 
 
cells were incubated
for 2 h at 37
 
 
 
C with 0.25 
 
 
 
M of the iodinated cysteine protease
inhibitor CBZ-
 
125
 
I-Tyr-Ala-CN
 
2 
 
(25). This inhibitor irreversibly
binds to the active site of cysteine proteases via a thiol–ester bond.
Cells were washed, lysed in cell lysis buffer (0.5% NP-40, 0.15 M
NaCl, 50 mM Tris-HCL, pH 7.2), supplemented with a cocktail
of protease inhibitors (Roche Molecular Biochemical), and run
on a 12% wt/vol SDS-PAGE gel. 
 
125
 
I-labeled proteins were visu-
alized by autoradiography on Kodak BioMax 
 
M
 
r 
 
film. The results
were quantified using the Bio-Rad GS-700 Imaging Densitome-
ter and analyzed by Multi-Analyzer software Version 1.0.2. Alter-
natively, 10
 
6 
 
cells were incubated for 2 h at 37
 
 
 
C with 0.25 
 
 
 
M
of the biotinylated cysteine proteinase inhibitor biotin-Tyr-Ala-
FMK, as described above. Intracellular biotin-labeled proteases
were detected by immunoblotting cell lysates (see below). Extra-
cellular cathepsin activity was analyzed by Western blot after con-
centrating supernatant by ultrafiltration on YM10 Centricons
(Amicon) and dialysis against 20 mM Tris, pH 7.5.
 
Immunoblotting.
 
M
 
 
 
s and fibroblasts were washed in PBS and
lysed as described above. Debris was removed by centrifugation at
8,000 rpm for 10 min and the lysates and supernatant were ana-
lyzed for protein content using Coomassie
 
® 
 
Plus Protein Assay
Reagent (Pierce Chemical Co.). Samples containing the indi-
cated amount of total protein or number of cell equivalents were
boiled for 5 min in SDS-reducing buffer and separated by 12%
SDS-PAGE. The proteins were electrophoretically transferred
onto nitrocellulose membrane and this was probed using the indi-
cated primary Ab. Binding was detected using the appropriate
horseradish peroxidase–conjugated secondary Ab diluted 1:1,000
and visualized by chemiluminescence (Amersham Biosciences).
 
Pulse Chase Biosynthetic Radiolabeling and Immunoprecipitation.
 
pM
 
 
 
s were preincubated at 37
 
 
 
C for 2 h in methionine/cysteine-
free RPMI 1640 supplemented with 200 mM 
 
l
 
-glutamine, 10T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
171
 
Beers et al.
 
mM Hepes, 100 
 
 
 
g/ml penicillin-streptomycin, and 5% dialyzed
FBS. Cells were pulsed (4–8 
 
  
 
10
 
6 
 
cells/ml) for 40 min with 1
mCi/ml 
 
35
 
S-methionine/cysteine (Trans 
 
35
 
S-label; ICN Biomed-
icals) and chased for 0, 1, 3, and 6 h in the presence of 30
 
  
 
unla-
beled methionine (3 mM) and cysteine (16 mM). Pulse-labeled
cells were washed in PBS and lysed in 1% NP-40, 0.01 M Tris,
pH 7.4, and 0.15 M NaCl supplemented with a cocktail of pro-
tease inhibitors (Roche Molecular Biochemicals). Before precipi-
tation with the M5/114 Ab, lysates were precleared with protein
G Sepharose (Amersham Biosciences) and normal rat IgG (Caltag
Laboratories Inc.). Precipitated proteins were boiled in SDS-re-
ducing buffer and separated by 7.5–20% gradient SDS-PAGE.
Gels were fixed in 50% methanol, 10% acetic acid, treated with
Amplify™
 
 
 
(Amersham Biosciences), dried, and the labeled pro-
teins were visualized by autoradiography.
 
RNA Extraction and cDNA Synthesis.
 
pM
 
 
 
s were purified by
adherence to bacterial plastic plates and were lysed in RNA
STAT-60 (3 ml RNA STAT-60 per 10   106 cells; TEL-TEST
“B” INC.) directly on the plates 30 min after plating (ex vivo)
and after 48 h of incubation in the presence or absence of IFN- .
RNA was extracted according to the manufacturer’s protocol and
contaminating DNA was removed by treating 2  g of sample
RNA with amplification grade DNase I (Life Technologies). First
strand cDNA was prepared by reverse transcription using the Life
Technologies SUPERSCRIPT™ First-Strand Synthesis System
for RT-PCR, as directed by the manufacturer.
Real-time PCR. Primer and probe sequences were selected
with the assistance of Primer Express software (Applied Biosys-
tems) using nucleotide sequences available on the GenBank Data-
base (available from GenBank/EMBL/DDBJ under accession
nos. NM_013556, X06086, and AJ002386 for HPRT, catL, and
catS, respectively). Primers (Life Technologies) are as follows:
HPRT-F 5 -3  (5 -TGGAAAGAATGTCTTGATTGTTGAA-
3 ); HPRT-R 5 -3   (5 -AGCTTGCAACCTTAACCATT-
TTG-3 ); CatL-F 5 -3   (5 -GACCGGGACAACCACTGTG-
3 ); CatL-R 5 -3   (5 -CTACCCATCAATTCACGAC-3 );
CatS-F 5 -3  (5 -GCCATTCCTCCTTCTTCTTCTACA-3 );
and CatS-R 5 -3   (5 -CAAGAACACCATGATTCACAT-
TGC-3 ). The following probes were synthesized with a 5  FAM
reporter and 3   TAMRA quencher (Biosearch Technologies
Inc.): HPRT (5 -6-FAM-CAAACTTTGCTTTCCCTGGTT-
AAGCAGTACAGC-TAMRA-3 ); CatL (5 -6-FAM-CTC-
AGGTGTTTGAACCCATGAATCTTTTACTC-TAMRA-3 );
and CatS (5 -6-FAM-AAGCGGTGTCTATGATGACCCCT-
CCTGTATAMRA-3 ).
Real-time PCR amplification of HPRT, catL, and catS was
performed as previously described (18). Triplicates of each cDNA
sample were amplified alongside appropriate controls and each as-
say was performed on at least three independent occasions. Rela-
tive quantitation of catL and catS expression was determined us-
ing the comparative CT method (user bulletin no. 2; Applied
Biosystems). This method was used to calculate the fold increase
of mRNA in pM s after 48 h of incubation in the presence or
absence of IFN-  compared with those cells isolated ex vivo.
Results
Ii Degradation in IFN- –stimulated M s Is Predominately
Mediated by CatS. The cysteinal lysosomal proteinases
catS and catL play a role in regulating the MHC class II
presentation pathway by virtue of their role as mediators of
the late stages of Ii degradation (8, 11–14). These enzymes
are differentially expressed in vivo in all APCs except M s,
in which both catS and catL activity can be detected. Thus,
we wished to determine the relative contribution of each
of these enzymes to Ii degradation and regulation of MHC
class II presentation by M s.
To elucidate the effects of catS and catL on the kinetics
of Ii degradation, thioglycollate-elicited pM s isolated
from B6, catL / , catS / , and catS /  xcatL /  mice
were cultured for 48 h in the presence of IFN-  to induce
up-regulation of MHC class II (26). IFN- –stimulated
pM s were metabolically labeled and chased for 0, 1, 3,
and 6 h. Protein lysates were immunoprecipitated with an
MHC class II–specific Ab and analyzed by SDS-PAGE
(Fig. 1 A). B6 pM s showed minimal accumulation of the
p12 fragment of Ii associated with MHC class II whereas in
catS /  cells marked accumulation of p12 was observed af-
ter 1 h of chase. This fragment was slowly degraded over
the 6 h of chase, suggesting that in the absence of catS an-
other proteinase is capable of Ii processing, albeit with sub-
stantially slower kinetics. The extent of p12 accumulation
in catL /  pM s was not significant compared with that
observed in catS /  pM s and therefore the delayed cleav-
age of Ii in the absence of catS is unlikely to be mediated
by catL. In addition, in the absence of both catS and catL
accumulation of p12 occurred with the same kinetics as ob-
served in pM s lacking catS alone.
To test whether the defect in Ii processing in the absence
of catS was limited to pM , we examined different M 
populations and analyzed the steady state levels of Ii. We
isolated alveolar, peritoneal, and BMM s from B6 and
catS /  mice (Fig. 2, B, C, and D). This experiment re-
vealed accumulation of p12 Ii fragments in all M  types in
the absence of catS. These results clearly implicate catS as
the key enzyme regulating the late stages of Ii degradation
in M s. In the absence of catS, another enzyme, likely
catF, might be able to degrade Ii, albeit with significantly
less efficiency.
IFN-  Stimulation of M s Modulates Cathepsin Activity.
The observation that catL played only a minor role in Ii
degradation in IFN- –treated pM s and previous reports
indicating that IFN-  modulates the mRNA level of ca-
thepsins (27–29) lead us to investigate the effect of IFN- 
on the level of catS and catL of activity in pM s and
BMM s. IL-4 has also been shown to up-regulate expres-
sion of MHC class II on the surface of M s (26) and it has
been shown that in DCs protease activity can be modulated
by both pro- and antiinflammatory cytokines (30). There-
fore, we sought to examine the effects of both IFN-  and
IL-4 on catS and catL activity in distinct M  populations.
Thioglycollate-elicited pM s and BMM s were isolated
from B6-, catL / -, and catS / -deficient mice and the
level of intracellular cathepsin activity was analyzed imme-
diately upon isolation (ex vivo) and after 48 h of culture in
the presence or absence of IFN-  or IL-4 (Fig. 2, A, B, and
C). pM s analyzed directly ex vivo had barely detectable
levels of catS and a very low level of catL activity. Upon
culture, in the absence of cytokines, both pM s and
BMM s showed a marked increase in catL activity whereasT
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the activity of catS increased only slightly. Interestingly, the
addition of IFN-  resulted in an increase in catS activity
and a dramatic decrease in catL activity. We quantified the
changes in catL activity after IFN-  stimulation by densi-
tometry and found catL activity decreased between 50–100-
fold (Fig. 2 C). IL-4, however, had no affect on cathepsin
activity as compared with M s cultured in the absence of
cytokines (unpublished data; see Figs. 4 and 5). These data
suggest our previous observation that catS but not catL was
critical for regulating the late stages of Ii cleavage in IFN-
 –stimulated M s can be explained by the effect of this cy-
tokine on down-modulating catL activity.
We have previously observed that the level of mature
catL protein in B cells is regulated by the presence or ab-
sence of catS (18). Thus, we wished to determine whether
such regulation of the cysteinal proteinases was involved in
the changes in cathepsin activity observed in both pM s
and BMM s cultured in the presence of cytokines. Modu-
lation of catL activity after IFN-  stimulation of catS-defi-
cient M s was comparable to that observed in B6-derived
cells (Fig. 2, A, B, and C), implying that in M s the activi-
ties of catS and catL are regulated independently upon
IFN-  stimulation.
CatL mRNA Levels Are Decreased upon IFN-  Stimulation
of pM s. Our finding that catL activity was decreased
upon IFN-  stimulation of pM s lead us to investigate the
mechanisms by which this down-modulation was regu-
lated. In view of several studies in which it has been re-
ported that in a variety of cell types cathepsin mRNA levels
are altered by IFN-  stimulation (27–29), we sought to de-
termine whether transcription of catL mRNA was de-
creased in pM s upon IFN-  stimulation.
pM s were purified by adherence to tissue culture plates
and mRNA was isolated from cells directly ex vivo and af-
ter culturing for 48 h in the presence or absence of IFN- .
Real time PCR amplification and subsequent quantitative
analysis indicated that the level of catL mRNA in IFN- –
stimulated pM s was decreased approximately eightfold
compared with cells analyzed directly ex vivo (Fig. 3). Fur-
thermore, we were unable to detect any significant change
Figure 1. Ii degradation in cathepsin-
deficient M s. (A) Thioglycollate-induced
M s from B6, catS / , catL / , and catS / 
xcatL /   mice were pulse labeled and
chased for 0, 1, 3, and 6 h. Cell lysates were
immunoprecipitated with the I-Ab-specific
Ab M5/114 and immunoprecipitates were
analyzed by 7.5–20% gradient SDS-PAGE
under denaturing conditions. (B) Thiogly-
collate-induced pM s, (C) BMM s, and
(D) alveolar M s from B6 and catS    mice
were cultured for 48 h in the presence of
IFN-  and immunoblotted with the mono-
clonal Ab IN-1. Cells were solubilized in
lysis buffer (1% NP-40/TBS in the presence
of protease inhibitors) and lysates were then
twofold serially diluted starting at 5  g of
total protein (alveolar M s are shown at 5
 g only). The position of Ii fragments p41,
p31, and p12 are indicated.T
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in the level of catL mRNA in cells cultured in the absence
of cytokine. In addition, we analyzed catS mRNA levels in
pM s and observed no significant changes with or without
cytokine treatment. These results are in agreement with
previously published data indicating that catL mRNA is
decreased in microglial cells stimulated with IFN-  (27)
and suggests that the IFN- –induced decrease in catL ac-
tivity might in part be a result of decreased transcription of
catL mRNA.
Mature CatL Protein Levels Are Not Reduced in IFN- –
treated pM s. Having demonstrated that the decrease in
catL activity in IFN- –stimulated pM s correlated with
diminished transcription of catL mRNA, we wished to
establish whether there was a corresponding decrease in
intracellular catL protein levels. We performed a twofold
serial dilution of cell lysate derived from B6 pM s iso-
lated directly ex vivo or cultured for 48 h in the presence
or absence of IFN- . Lysates were separated by SDS-
PAGE and analyzed by immunoblotting for catL protein
(Fig. 4 A). Unexpectedly, we observed that the amount of
mature catL protein detected in pM s cultured in the
presence or absence of IFN-  was comparable and that
this level of protein was substantially greater than that de-
tected in ex vivo–isolated cells. A decrease in the amount
of the 38 kD pro-form of catL was observed, however, in
IFN- –stimulated pM s when compared with cells ana-
lyzed directly ex vivo. Thus, the reduction in catL
mRNA upon IFN-  stimulation of pM s resulted in a
decrease in pro-form catL protein although there was no
significant concomitant decrease in the level of mature
catL protein, presumably as a result of the long half-life of
this protein. Taken together, our results demonstrating
that catL activity is substantially diminished upon IFN- 
stimulation of pM s whereas levels of mature catL pro-
Figure 2. Active site labeling of cytokine-treated M . (A) Thioglycollate-induced pM s and (B) BMM s from B6, catS / , and catL /  mice were
either taken directly ex vivo or activated for 48 h with or without IFN- . Cells were incubated for 2 h with the irreversible cysteine protease inhibitor
Cbz- [125I]-Tyr-Ala-CN2. Cells were lysed and radiolabeled enzymes were analyzed on a 12% SDS-PAGE gel. Levels of active cathepsin in cells taken di-
rectly ex vivo (ex vivo) and after 48 h of plating with IFN-  (IFN- ) or without (UN) are shown. The position of cathepsin B (catB), cathepsin S (catS),
and cathepsin L (catL) are indicated on the gel. C) The intensity of the active site labeling was quantified by the BioRad GS-700 Imaging Densitometer
and analyzed by Multi-Analyzer software Version 1.0.2. The numbers correspond to the following: 1, B6 ex vivo; 2, B6 UN; 3, B6 IFN- ; 4, catS    ex
vivo; 5, catS    IFN- ; 6, catS    UN; 7, catL    ex vivo; 8, catL    UN; 9, catL    IFN- .
Figure 3. Regulation of catL activity by mRNA. pM s were purified
by adherence to bacterial plastic plates. Cells were lysed directly on the
plates 30 min after plating (ex vivo) and after 48 h of incubation in the
presence or absence of IFN- . After RNA extraction and cDNA synthe-
sis, quantitative PCR was performed in an ABI Prism 7700 sequence de-
tector. Primers and probes for HPRT, catL and catS were designed using
Primer Express software. The probes were labeled at the 5  and 3  ends
with the fluorochromes FAM and TAMRA. mRNA levels were quanti-
tated using the comparative CT method described in the ABI Prism 7700
sequence detector user bulletin number 2. The data is shown as the level
of cathepsin mRNA in cells after 48 h of plating with IFN-  (IFN- ) or
without (UN) compared with the level of mRNA ex vivo.T
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tein are increased suggest an inhibitor of catL might be
up-regulated in these cells.
Modulation of CatL Activity in IFN- –stimulated pM s Oc-
curs in the Absence of Ii. Several molecules have been im-
plicated as inhibitors of catL, including the p41 isoform of Ii
(31–33). Previous studies have shown that Ii is up-regulated
in response to IFN-  (20), making p41 an attractive candi-
date inhibitor of catL in pM s cultured in the presence of
this cytokine. Thus, we examined the regulation of catL in
thioglycollate-elicited pM s isolated from Ii /  mice.
To first test whether p41 could be an inhibitor of catL
activity in IFN- –stimulated pM s, we analyzed by im-
munoblotting the level of Ii protein in B6 pM s isolated
directly ex vivo or cultured in the presence or absence of
IFN-  for 48 h (Fig. 4 B). Upon IFN-  stimulation the
p41 isoform of Ii was substantially up-regulated whereas
the increase in p31 was more moderate. No such change in
the level of either p31 or p41 was observed when cells
were cultured in the absence of cytokine. This increase in
p41 upon IFN-  stimulation of pM s provided us with ev-
idence that p41 was a viable candidate inhibitor of catL.
It has previously been reported that the level of mature
catL protein detected in BMM s is significantly decreased
in the absence of the p41 isoform of Ii (33). Therefore, we
sought to determine whether a similar defect could be ob-
served in Ii /  pM s. The level of catL protein in pM s
isolated from Ii /  mice was analyzed by serial dilution of
cell lysates and immunoblotting as described above. The
level of mature catL protein in Ii /  pM s was increased
upon culturing the cells in the presence or absence of
IFN-  (Fig. 4 C), as observed in B6 pM s (Fig. 4 A). The
extent of up-regulation of mature catL in cells cultured in
the absence of cytokine was the same for both Ii /  and
B6-derived cells. However, the amount of mature catL
protein detected in Ii /  cells cultured in the presence of
IFN-  was two- to threefold less than in cells cultured in
the absence of this cytokine and also two- to threefold less
than in B6 pM s cultured in IFN-  (Fig. 4 A). Taken to-
gether, these data suggest that p41 may play some role in
stabilizing the mature form of catL in IFN- –stimulated
pM s as has been suggested for BMM s (33), however,
we observed no role for p41 in maintaining the level of
mature catL protein in pM s isolated directly ex vivo or
cultured in the absence of cytokines.
Having observed that Ii /  pM s stimulated with IFN- 
express noticeably lower levels of mature catL protein than
B6 cells cultured under the same conditions, we aimed to
establish whether Ii regulated the decrease in catL activity
detected upon IFN-  stimulation of B6 M s. pM s and
BMM s from B6 and Ii /  mice were isolated directly ex
vivo or cultured for 48 h in the presence or absence of
IFN-  or IL-4. Intracellular cathepsin activity was detected
using the irreversible cysteine protease inhibitor Cbz-125I-
Tyr-Ala-CN2 and the proteins were separated by SDS-
Figure 4. CatL and the effect of the p41 Ii isoform.
The level of catL in (A) B6 and (C) Ii /  thioglycollate-
induced pM s cultured for 48 h in the presence or ab-
sence of IFN-  was detected by immunoblotting with a
catL-specific polyclonal antiserum. Cells were solubilized
in lysis buffer (1% NP-40/TBS in the presence of pro-
tease inhibitors) and lysates were then twofold serially di-
luted starting at 40  g of total protein. Arrows indicate
pro-catL and mature catL. These experiments were per-
formed three times and yielded identical results. (B)
Thioglycollate-induced pM s from B6 mice were taken
directly ex vivo or activated for 48 h in the presence or
absence of IFN- . Cells were solubilized in lysis buffer
(1% NP-40/TBS in the presence of protease inhibitors).
20  g of lysate was separated on a 12% SDS-PAGE and
immunoblotted with the IN-1 Ab. p41 and p31 are indi-
cated. (D) Thioglycollate-induced pM s and (E) BMM s
from B6 and Ii /  mice were cultured for 48 h in the
presence or absence of IFN- . 106 cells were incubated
for 2 h with the irreversible cysteine protease inhibitor
Cbz-[125I]-Tyr-Ala-CN2, lysed, and separated by 12%
SDS-PAGE. Levels of active cathepsin in cells taken directly ex vivo (ex vivo) and after 48 h of plating with IFN-  (IFN- ) or without (UN) are shown.
Arrows indicate the positions of cathepsin B (catB), cathepsin S (catS), and cathepsin L (catL).T
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PAGE (Fig. 4, D and E). The modulation of cathepsin ac-
tivity we observed was the same in both cell types. After
culture of cells in the absence of cytokine catL activity was
up-regulated and in the presence of IFN-  this up-regula-
tion was not observed. In addition, catL activity was up-
regulated in cells cultured in the presence of IL-4. These
results provide no evidence for a major role for the p41 iso-
form of Ii in regulating catL activity in pM s and BMM s
although it may play a modest role in stabilizing the levels
of mature catL protein in IFN- –stimulated M s.
CatL Is Secreted When M s Are Treated with IFN- .
Cathepsins are soluble proteinases and specific secretion of
catL may explain the decrease in intracellular catL activity
we observed upon IFN-  stimulation of pM s. To address
this possibility we compared intracellular and extracellular
cathepsin activity using a new biotinylated active site label-
ing reagent, biotin-Tyr-Ala-FMK. pM s were labeled for
2 h at 37 C with the biotinylated inhibitor and labeled en-
zymes in the culture supernatant and cell lysates were de-
tected by Western blot analysis. As shown in Fig. 5, A and
B, catL activity was markedly increased in the culture su-
pernatant upon IFN-  treatment whereas intracellular catL
activity sharply decreased. CatL activity was barely detect-
able in supernatant of untreated or IL-4–treated pM s. In
contrast, both extracellular and intracellular catS activity in-
creased upon treatment with IFN- . It is important to note
that endocytic uptake can be a rate-limiting step, thus, the
efficiency of the active site labeling of intracellular enzymes
is significantly less efficient than that of extracellular en-
zymes. Therefore, we assessed the overall amount of catL
protein secreted by IFN- –induced pM s by Western blot
analysis with an anti-catL Ab (Fig. 5 D). We observed a
two- to fourfold increase in mature catL whereas pro-catL
levels are decreased in the supernatant of IFN- –treated
cells as compared with the cells cultured in the absence of
cytokine. In these experiments analyzing catL levels in cul-
ture supernatants, we used 7–10-fold more cell equivalents
per lane as compared with intracellular catL analysis. Taken
together with intracellular mature catL protein levels not
changing, these experiments indicate that secretion of catL
protein cannot account for the significant loss in catL activ-
ity upon IFN-  stimulation of pM s.
Cathepsins have been implicated in inflammatory extra-
cellular matrix remodeling, tumor metastasis, and angiogen-
esis (34) and catL has a potent elastinolytic activity (35). We
wanted to determine if the secreted enzymes are active ex-
tracellularly by labeling supernatants of pM  cultures with
biotin-Tyr-Ala-FMK at neutral pH and found that both se-
creted catL and catS are active at physiological pH (Fig. 5
C). This data suggests that secreted catL may play a role in
extracellular matrix remodeling at the sites of inflammation.
CatL Activity Is Inhibited When Overexpressed in DCs. B
cells and DCs exhibit no catL activity and therefore utilize
catS for late stage Ii chain processing whereas M s are the
only APC in which active catS and catL can be detected
concurrently. In light of our observation that catL plays
no significant role in Ii degradation in M s, we sought to
investigate the effect of catL expression in a second catS-
dependent APC. tg mice were generated using the
CD11c promoter to specifically overexpress catL in DCs.
To rule out any effect of catS upon MHC class II matura-
tion in these cells, these mice were crossed onto a catS / 
background.
We wished to determine the level of catL protein ex-
pressed in DCs isolated from tg mice and non-tg littermate
control animals. Highly purified DCs were isolated and
protein lysates from the indicated number of cells were an-
alyzed for catL protein (Fig. 6). B6 DCs expressed signifi-
cantly less catL protein than the equivalent number of
CD11c-catL tg DCs, indicating that the CD11c promoter
efficiently induces overexpression of catL protein in DCs.
To our surprise, using the Cbz-125I-Tyr-Ala-CN2 irrevers-
ible inhibitor we were unable to detect catL activity in the
CD11c-catL tg DCs in which we observed high levels of
mature catL protein. We observed the same results using
DCs isolated from progeny of a second founder CD11c-
catL tg mouse (unpublished data).
Figure 5. Secretion of catL upon IFN-  treatment. B6 thioglycollate-
induced pM s taken directly ex vivo or cultured for 48 h in the presence
or absence of IFN-  or IL-4 were incubated serum free with the cysteine
proteinase inhibitor biotin-Tyr-Ala-FMK for 2 h. Labeled cathepsin
present (A) intracellularly and (B) in the supernatant were detected by
immunoblotting. (C) Cells were incubated for 2 h in serum-free medium,
the cells were removed, and the inhibitor biotin-Tyr-Ala-FMK was added
for 20 min before analysis of labeled cathepsins by immunoblotting. (D)
Thioglycollate-elicited pM s cultured for 48 h in the presence or absence
of IFN-  were incubated for 2 h in serum-free medium. 5  g of total su-
pernatant protein were titrated and separated before catL immunoblotting.T
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To ensure that the level of mature catL protein expressed
by the CD11c-catL tg DCs generates sufficient signal to be
detected in our active site labeling assay, we compared catL
protein and activity in tg DCs to fibroblasts, a cell type
known to express high levels of catL activity (11). We were
able to detect both mature catL protein and catL activity in
as few as 8,000 fibroblast cells (Fig. 6). However, in DCs
expressing comparable catL protein levels to 1.25   105 fi-
broblasts we were unable to detect catL activity. Thus, the
quantity of mature catL protein expressed in the CD11c-
catL tg DCs is not below the level of detection in our ac-
tive site labeling assay, indicating that DCs express a spe-
cific inhibitor of catL activity.
Discussion
The lysosomal cysteinal proteinases catS and catL have
previously been shown to play a critical role in the late
stages of Ii degradation in DCs, B cells, and cortical thymic
epithelial cells (36, 37). In these cells, activity of only one
enzyme can be detected and thus the relative role of catS
and catL in regulating Ii processing cannot be assessed.
M s provide an ideal APC in which to study whether catS
and catL are redundant enzymes in the regulation of MHC
class II presentation, as activity of both enzymes can be de-
tected in these cells. Here, we report that in thioglycollate-
elicited pM s stimulated with IFN- , catS is principally
responsible for mediating Ii cleavage whereas catL plays lit-
tle part in this process. This result is surprising given that
efficient Ii proteolysis in cortical thymic epithelial cells re-
quires catL and that in MHC class II–expressing fibroblast
cell lines effective Ii cleavage can be mediated by catL (11,
38). However, an explanation for our results is provided by
our subsequent observation that although intracellular ac-
tivity of catL is profoundly down-regulated in pM s in re-
sponse to the proinflammatory cytokine IFN- , intracellu-
lar catS activity increases. This modulation in catL activity
in IFN- –stimulated pM s coincided with a decrease in
catL mRNA levels whereas catS mRNA levels were not
diminished. These data indicate that modulation of catL ac-
tivity in pM s in response to IFN-  is in part regulated at
the level of transcription as has previously been reported for
microglial cells (27). Down-regulation of catL mRNA was
concomitant with a decrease in pro-catL, however, levels
of the mature protein were not decreased in IFN- –stimu-
lated pM s. One possible explanation for this maintenance
of high levels of mature catL protein despite decreased
mRNA is that the mature enzyme is long lived in endo-
somes. Additional studies showed that the decrease in catL
activity upon IFN-  stimulation was concomitant with an
increase in secretion of mature catL protein that exhibited
protease activity. However, this increase in secretion had
little effect on intracellular catL protein levels and there-
fore, secretion of mature protein does not explain the spe-
cific inhibition of intracellular catL activity. Taken together
with our observation that intracellular catL activity de-
creases in IFN- –stimulated pM s whereas levels of the
mature protein are maintained, these results suggest that an
inhibitor(s) of enzyme activity is increased in response to
this proinflammatory cytokine and is critical for regulating
catL activity in pM s and BMM s.
A number of lysosomal cysteinal proteinases inhibitors
have been identified, including cystatin C (39, 40), the
propeptide regions of the cathepsins (41–43), and the p41
isoform of Ii (31, 32). We found no difference in cystatin C
expression or localization in pM s cultured in the presence
or absence of IFN-  (unpublished data), indicating that this
cysteinal proteinase inhibitor plays no significant role in
regulating catL activity upon IFN-  stimulation of pM s.
In addition, the propeptide regions of catS and cathepsin B
(catB) do not affect the level of catL activity in M s treated
with IFN- . We examined catS- and catB-deficient pM s
and BMM s and were unable to determine any differences
in catL activity with or without treatment of IFN-  when
compared with B6 M s (Fig. 2 and unpublished data). Re-
cent studies have reported that p41 is not only an inhibitor
of catL enzymatic activity but that it is also required for
catL activity in BMM s where it acts as a chaperone, stabi-
lizing the mature form of this enzyme (33). Because both
MHC class II and Ii, including p41, are up-regulated in
pM s stimulated with IFN- , we examined whether p41
and its fragments were responsible for the observed down-
regulation of catL activity and preservation of high levels of
mature protein in these cells. We observed that levels of
mature catL protein in Ii    and B6 pM s and BMM s
were identical, except upon IFN-  stimulation when catL
levels were two- to threefold lower in Ii    cells compared
with B6 cells. However, we detected equivalent levels of
catL activity in Ii    and B6 pM s and BMM s cultured in
the presence or absence of IFN- . Furthermore, the extent
Figure 6. Inhibition of catL activity in CD11c-catL tg
mice. DCs purified from Flt3 ligand–treated CD11c-catL tg
mice were twofold serially diluted starting at 106  cells.
Transformed murine embryonic fibroblasts were twofold
serially diluted starting at 2.5   105 cells. For Western blot
analysis, cells were solubilized in lysis buffer (1% NP-40/
TBS in the presence of protease inhibitors) and lysates were
separated by 12% SDS-PAGE and immunoblotted for catL.
Pro-catL and mature catL are indicated. For active site la-
beling, cells were incubated for 2 h with the irreversible
cysteine protease inhibitor Cbz-[125I]-Tyr-Ala-CN2. Cells
were lysed and radiolabeled enzymes were analyzed on a
12% SDS-PAGE gel. Arrows indicate active catL.T
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to which catL activity was down-regulated upon IFN- 
stimulation was equivalent in Ii    and B6 cells. These data
demonstrate that Ii does not play an important role in regu-
lating catL activity in either thioglycollate-induced pM s
or BMM s and are in agreement with our previous obser-
vations in thymic stromal cells (15). However, these results
suggest that Ii does play a minor role in stabilizing the ma-
ture form of catL in pM s, as has been previously sug-
gested by others for BMM s (33). Another possible inhibi-
tor of catL activity is cystatin F, which is specifically
expressed in hematopoietic cells and preferentially binds
catL and papain in vitro (44, 45). We believe cystatin F
could potentially be involved in the catL inhibition ob-
served in M s or DCs and would like to investigate this in
the future. Thus, although it is possible that p41 may con-
tribute modestly to the observed down-modulation of in-
tracellular catL activity upon IFN-  stimulation of pM s,
we suggest that an unknown inhibitor is the pivotal regula-
tor of catL enzymatic activity in pM s.
We have previously reported that catL activity cannot be
detected in ex vivo–isolated DCs (11, 18), however, signif-
icant levels of catL activity can be detected in DCs derived
from bone marrow in culture (unpublished data). In view
of our observations implying that catL activity in pM s is
regulated in a highly specific manner by an as yet unidenti-
fied inhibitor, we sought to examine whether such a mech-
anism was present in ex vivo DCs. Analysis of DCs isolated
from the spleen of mice engineered to express catL under
the control of the CD11c promoter revealed significant
levels of mature catL protein but no detectable catL activity
in these cells. Expression of this catL cDNA when driven
by a retroviral promoter in fibroblasts generated high levels
of catL activity (38), indicating that inhibition of enzymatic
activity was specific to ex vivo–isolated DCs. Thus, we
have shown that both DCs and pM s use a mechanism of
catL inhibition although the nature of the catL inhibitor in
DCs and pM s remains to be identified.
Our data indicate that catL activity is down-regulated
upon IFN-  stimulation of pM s and that catS is the pre-
dominant mediator of the late stages of Ii degradation, and
hence MHC class II peptide presentation. In addition, catS
mediates Ii degradation in other M  populations. These
observations appear to differ from a recent report in which
it was shown that other cysteinal proteinases, perhaps catF,
are able to compensate for the absence of catS and catL and
elicit degradation of Ii in pM s and alveolar M s (16).
However, in this latter study, Ii processing was analyzed
immediately after pulse and after an overnight chase. Thus,
the pronounced accumulation of MHC class II–associated
p12 Ii fragments we observe between 1 and 6 h of chase
was not detected. The significantly delayed kinetics of Ii
degradation and accumulation of MHC class II–bound Ii
fragments in catS-deficient pM s affect the efficiency of
generation of MHC class II–peptide complexes and thus
account for the previously reported defect in MHC class II
presentation of some but not other protein antigens (13).
Therefore, we believe that while although enzymes can
mediate Ii cleavage with delayed kinetics, catS plays a ma-
jor role in regulating Ii degradation and MHC class II pre-
sentation in M s.
In conclusion, we have shown that in pM s, in which
both cysteinal proteinases catS and catL are expressed, catS
is the predominant enzyme processing Ii. Furthermore,
catL is shown to have no major role in this process as a re-
sult of substantial down-regulation of its enzymatic activity
upon IFN-  stimulation. This decline in catL activity cor-
relates with a decrease in catL mRNA and an increase in
secretion of mature catL protein but not a decrease in intra-
cellular mature catL protein levels, suggesting that catL ac-
tivity in IFN- –stimulated pM s is regulated by a specific
inhibitor. In addition, we find the p41 isoform of Ii does
not contribute significantly to this regulation of catL activ-
ity in pM s and that DCs also use a catL-specific inhibition
mechanism. The results presented here indicate that upon
IFN-  activation of pM s, enzymatic activity of catL is
specifically inhibited, such that catS mediates Ii degradation
and regulates MHC class II maturation. Thus, we suggest
that as a result of differential regulation of catL and catS the
latter enzyme governs MHC class II presentation by APCs
in secondary lymphoid organs.
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